{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:19:35Z","timestamp":1791908375716,"version":"4.3.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T00:00:00Z","timestamp":1630368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T00:00:00Z","timestamp":1630368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018854","name":"Sirtex","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018854","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the correlation between liver enhancement on hepatobiliary phase and liver function parameters in a multicenter, multivendor study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 359 patients who underwent gadoxetic acid\u2013enhanced MRI using a standardized protocol with various scanners within a prospective multicenter phase II trial (SORAMIC) were evaluated. The correlation between liver enhancement on hepatobiliary phase normalized to the spleen (liver-to-spleen ratio, LSR) and biochemical laboratory parameters, clinical findings related to liver functions, liver function grading systems (Child-Pugh and Albumin-Bilirubin [ALBI]), and scanner characteristics were analyzed using uni- and multivariate analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      There was a significant positive correlation between LSR and albumin (rho = 0.193;\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001), platelet counts (rho = 0.148;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.004), and sodium (rho = 0.161;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.002); and a negative correlation between LSR and total bilirubin (rho = \u22120.215;\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001) and AST (rho = \u22120.191;\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001). Multivariate analysis confirmed independent significance for each of albumin (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.022), total bilirubin (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.045), AST (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.031), platelet counts (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.012), and sodium (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.006). The presence of ascites (1.47 vs. 1.69,\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001) and varices (1.55 vs. 1.69,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.006) was related to significantly lower LSR. Similarly, patients with ALBI grade 1 had significantly higher LSR than patients with grade 2 (1.74 \u00b1 0.447 vs. 1.56 \u00b1 0.408,\n                      <jats:italic>p &lt;<\/jats:italic>\n                      0.001); and Child-Pugh A patients had a significantly higher LSR than Child-Pugh B (1.67 \u00b1 0.44 vs. 1.49 \u00b1 0.33,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.021). Also, LSR was negatively correlated with MELD-Na scores (rho = \u22120.137;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.013). However, one scanner brand was significantly associated with lower LSR (\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The liver enhancement on the hepatobiliary phase of gadoxetic acid\u2013enhanced MRI is correlated with biomarkers of liver functions in a multicenter cohort. However, this correlation shows variations between scanner brands.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key Points<\/jats:title>\n                    <jats:p>\n                      <jats:italic>\u2022 The correlation between liver enhancement on the hepatobiliary phase of gadoxetic acid\u2013enhanced MRI and liver function is consistent in a multicenter-multivendor cohort.<\/jats:italic>\n                    <\/jats:p>\n                    <jats:p>\n                      <jats:italic>\u2022 Signal intensity\u2013based indices (liver-to-spleen ratio) can be used as an imaging biomarker of liver function.<\/jats:italic>\n                    <\/jats:p>\n                    <jats:p>\n                      <jats:italic>\u2022 However, absolute values might change between vendors.<\/jats:italic>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00330-021-08218-9","type":"journal-article","created":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T15:02:36Z","timestamp":1630422156000},"page":"1320-1329","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Correlation of liver enhancement in gadoxetic acid\u2013enhanced MRI with liver functions: a multicenter-multivendor analysis of hepatocellular carcinoma patients from SORAMIC trial"],"prefix":"10.1007","volume":"32","author":[{"given":"Osman","family":"\u00d6cal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bora","family":"Peynircioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Loewe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto","family":"van Delden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Vandecaveye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Gebauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph J.","family":"Zech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Sengel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Bargellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Iezzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Benito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Sch\u00fctte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gasbarrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricarda","family":"Seidensticker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz","family":"Wildgruber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Pech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Malfertheiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Ricke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Seidensticker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,31]]},"reference":[{"key":"8218_CR1","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1007\/s00330-009-1467-6","volume":"19","author":"U Motosugi","year":"2009","unstructured":"Motosugi U, Ichikawa T, Tominaga L et al (2009) Delay before the hepatocyte phase of Gd-EOB-DTPA-enhanced MR imaging: is it possible to shorten the examination time? Eur Radiol 19:2623\u20132629","journal-title":"Eur Radiol"},{"key":"8218_CR2","doi-asserted-by":"publisher","first-page":"6593","DOI":"10.1007\/s00330-020-06930-6","volume":"30","author":"R Hayoz","year":"2020","unstructured":"Hayoz R, Vietti-Violi N, Duran R, Knebel JF, Ledoux JB, Dromain C (2020) The combination of hepatobiliary phase with Gd-EOB-DTPA and DWI is highly accurate for the detection and characterization of liver metastases from neuroendocrine tumor. Eur Radiol 30:6593\u20136602","journal-title":"Eur Radiol"},{"key":"8218_CR3","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1053\/j.sult.2016.08.005","volume":"37","author":"AD Karaosmanoglu","year":"2016","unstructured":"Karaosmanoglu AD, Onur MR, Ozmen MN, Akata D, Karcaaltincaba M (2016) Magnetic Resonance imaging of liver metastasis. Semin Ultrasound CT MR 37:533\u2013548","journal-title":"Semin Ultrasound CT MR"},{"key":"8218_CR4","doi-asserted-by":"publisher","first-page":"100173","DOI":"10.1016\/j.jhepr.2020.100173","volume":"2","author":"J Ricke","year":"2020","unstructured":"Ricke J, Steffen IG, Bargellini I et al (2020) Gadoxetic acid-based hepatobiliary MRI in hepatocellular carcinoma. JHEP Rep 2:100173","journal-title":"JHEP Rep"},{"key":"8218_CR5","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1016\/j.ejrad.2016.10.010","volume":"85","author":"Y Takatsu","year":"2016","unstructured":"Takatsu Y, Kobayashi S, Miyati T, Shiozaki T (2016) Hepatobiliary phase images using gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid-enhanced MRI as an imaging surrogate for the albumin-bilirubin grading system. Eur J Radiol 85:2206\u20132210","journal-title":"Eur J Radiol"},{"key":"8218_CR6","doi-asserted-by":"publisher","first-page":"6600","DOI":"10.1007\/s00330-019-06182-z","volume":"29","author":"L Beer","year":"2019","unstructured":"Beer L, Mandorfer M, Bastati N et al (2019) Inter- and intra-reader agreement for gadoxetic acid-enhanced MRI parameter readings in patients with chronic liver diseases. Eur Radiol 29:6600\u20136610","journal-title":"Eur Radiol"},{"key":"8218_CR7","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1002\/jmri.21956","volume":"30","author":"U Motosugi","year":"2009","unstructured":"Motosugi U, Ichikawa T, Sou H et al (2009) Liver parenchymal enhancement of hepatocyte-phase images in Gd-EOB-DTPA-enhanced MR imaging: which biological markers of the liver function affect the enhancement? J Magn Reson Imaging 30:1042\u20131046","journal-title":"J Magn Reson Imaging"},{"key":"8218_CR8","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1007\/s00535-012-0740-7","volume":"48","author":"HY Kim","year":"2013","unstructured":"Kim HY, Choi JY, Park CH et al (2013) Clinical factors predictive of insufficient liver enhancement on the hepatocyte-phase of Gd-EOB-DTPA-enhanced magnetic resonance imaging in patients with liver cirrhosis. J Gastroenterol 48:1180\u20131187","journal-title":"J Gastroenterol"},{"key":"8218_CR9","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.mri.2014.02.017","volume":"32","author":"S Matsushima","year":"2014","unstructured":"Matsushima S, Sato Y, Yamaura H et al (2014) Visualization of liver uptake function using the uptake contrast-enhanced ratio in hepatobiliary phase imaging. Magn Reson Imaging 32:654\u2013659","journal-title":"Magn Reson Imaging"},{"key":"8218_CR10","doi-asserted-by":"publisher","first-page":"5813","DOI":"10.1007\/s00330-019-06179-8","volume":"29","author":"S Matoori","year":"2019","unstructured":"Matoori S, Froehlich JM, Breitenstein S et al (2019) Serum albumin, total bilirubin, and patient age are independent confounders of hepatobiliary-phase gadoxetate parenchymal liver enhancement. Eur Radiol 29:5813\u20135822","journal-title":"Eur Radiol"},{"key":"8218_CR11","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.mri.2012.01.004","volume":"30","author":"A Higaki","year":"2012","unstructured":"Higaki A, Tamada T, Sone T et al (2012) Potential clinical factors affecting hepatobiliary enhancement at Gd-EOB-DTPA-enhanced MR imaging. Magn Reson Imaging 30:689\u2013693","journal-title":"Magn Reson Imaging"},{"key":"8218_CR12","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.ejrad.2014.11.014","volume":"84","author":"M Onoda","year":"2015","unstructured":"Onoda M, Hyodo T, Murakami T et al (2015) Optimizing signal intensity correction during evaluation of hepatic parenchymal enhancement on gadoxetate disodium-enhanced MRI: comparison of three methods. Eur J Radiol 84:339\u2013345","journal-title":"Eur J Radiol"},{"key":"8218_CR13","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1148\/radiol.2016151061","volume":"281","author":"M Okada","year":"2016","unstructured":"Okada M, Murakami T, Kuwatsuru R et al (2016) Biochemical and clinical predictive approach and time point analysis of hepatobiliary phase liver enhancement on Gd-EOB-DTPA-enhanced MR images: a multicenter study. Radiology 281:474\u2013483","journal-title":"Radiology"},{"key":"8218_CR14","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1007\/s00261-019-02036-w","volume":"44","author":"D Theilig","year":"2019","unstructured":"Theilig D, Elkilany A, Schmelzle M et al (2019) Consistency of hepatocellular gadoxetic acid uptake in serial MRI examinations for evaluation of liver function. Abdom Radiol (NY) 44:2759\u20132768","journal-title":"Abdom Radiol (NY)"},{"key":"8218_CR15","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.jhep.2019.08.006","volume":"71","author":"J Ricke","year":"2019","unstructured":"Ricke J, Kl\u00fcmpen HJ, Amthauer H et al (2019) Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. J Hepatol 71:1164\u20131174","journal-title":"J Hepatol"},{"key":"8218_CR16","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1002\/bjs.10095","volume":"103","author":"Y Wang","year":"2016","unstructured":"Wang Y, Zhong J, Su Z et al (2016) Albumin-bilirubin versus Child-Pugh score as a predictor of outcome after liver resection for hepatocellular carcinoma. Br J Surg 103:725\u2013734","journal-title":"Br J Surg"},{"key":"8218_CR17","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1136\/gut.2006.102764","volume":"56","author":"M-C Londo\u00f1o","year":"2007","unstructured":"Londo\u00f1o M-C, C\u00e1rdenas A, Guevara M et al (2007) MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation. Gut 56:1283\u20131290","journal-title":"Gut"},{"key":"8218_CR18","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1111\/jgh.13608","volume":"32","author":"PH Liu","year":"2017","unstructured":"Liu PH, Hsu CY, Hsia CY et al (2017) ALBI and PALBI grade predict survival for HCC across treatment modalities and BCLC stages in the MELD Era. J Gastroenterol Hepatol 32:879\u2013886","journal-title":"J Gastroenterol Hepatol"},{"key":"8218_CR19","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","volume":"33","author":"PJ Johnson","year":"2015","unstructured":"Johnson PJ, Berhane S, Kagebayashi C et al (2015) Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach\u2014the ALBI grade. J Clin Oncol 33:550","journal-title":"J Clin Oncol"},{"key":"8218_CR20","doi-asserted-by":"publisher","first-page":"S100","DOI":"10.1016\/j.jhep.2004.11.015","volume":"42","author":"F Durand","year":"2005","unstructured":"Durand F, Valla D (2005) Assessment of the prognosis of cirrhosis: Child\u2013Pugh versus MELD. J Hepatol 42:S100\u2013S107","journal-title":"J Hepatol"},{"key":"8218_CR21","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1053\/j.gastro.2006.02.010","volume":"130","author":"SW Biggins","year":"2006","unstructured":"Biggins SW, Kim WR, Terrault NA et al (2006) Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology 130:1652\u20131660","journal-title":"Gastroenterology"},{"key":"8218_CR22","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3109\/00365528909093045","volume":"24","author":"I Albers","year":"1989","unstructured":"Albers I, Hartmann H, Bircher J, Creutzfeldt W (1989) Superiority of the Child-Pugh classification to quantitative liver function tests for assessing prognosis of liver cirrhosis. Scand J Gastroenterol 24:269\u2013276","journal-title":"Scand J Gastroenterol"},{"key":"8218_CR23","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1148\/radiol.10091557","volume":"255","author":"T Tsuboyama","year":"2010","unstructured":"Tsuboyama T, Onishi H, Kim T et al (2010) Hepatocellular carcinoma: hepatocyte-selective enhancement at gadoxetic acid-enhanced MR imaging--correlation with expression of sinusoidal and canalicular transporters and bile accumulation. Radiology 255:824\u2013833","journal-title":"Radiology"},{"key":"8218_CR24","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.hpb.2019.09.009","volume":"22","author":"C Morin","year":"2020","unstructured":"Morin C, Drolet S, Daigle C et al (2020) Additional value of gadoxetic acid-enhanced MRI to conventional extracellular gadolinium-enhanced MRI for the surgical management of colorectal and neuroendocrine liver metastases. HPB (Oxford) 22:710\u2013715","journal-title":"HPB (Oxford)"},{"key":"8218_CR25","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s40644-019-0263-z","volume":"19","author":"D Puhr-Westerheide","year":"2019","unstructured":"Puhr-Westerheide D, Cyran CC, Sargsyan-Bergmann J et al (2019) The added diagnostic value of complementary gadoxetic acid-enhanced MRI to (18)F-DOPA-PET\/CT for liver staging in medullary thyroid carcinoma. Cancer Imaging 19:73","journal-title":"Cancer Imaging"},{"key":"8218_CR26","doi-asserted-by":"publisher","first-page":"e0215752","DOI":"10.1371\/journal.pone.0215752","volume":"14","author":"N Verloh","year":"2019","unstructured":"Verloh N, Probst U, Utpatel K et al (2019) Influence of hepatic fibrosis and inflammation: correlation between histopathological changes and Gd-EOB-DTPA-enhanced MR imaging. PLoS One 14:e0215752","journal-title":"PLoS One"},{"key":"8218_CR27","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1124\/dmd.110.032862","volume":"38","author":"M Leonhardt","year":"2010","unstructured":"Leonhardt M, Keiser M, Oswald S et al (2010) Hepatic uptake of the magnetic resonance imaging contrast agent Gd-EOB-DTPA: role of human organic anion transporters. Drug Metab Dispos 38:1024\u20131028","journal-title":"Drug Metab Dispos"},{"key":"8218_CR28","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1007\/s00330-015-3873-2","volume":"26","author":"EM Merkle","year":"2016","unstructured":"Merkle EM, Zech CJ, Bartolozzi C et al (2016) Consensus report from the 7th International Forum for Liver Magnetic Resonance Imaging. Eur Radiol 26:674\u2013682","journal-title":"Eur Radiol"},{"key":"8218_CR29","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394\u2013424","journal-title":"CA Cancer J Clin"},{"key":"8218_CR30","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1200\/JCO.2015.64.7412","volume":"34","author":"JL Petrick","year":"2016","unstructured":"Petrick JL, Kelly SP, Altekruse SF, McGlynn KA, Rosenberg PS (2016) Future of hepatocellular carcinoma incidence in the United States forecast through 2030. J Clin Oncol 34:1787\u20131794","journal-title":"J Clin Oncol"},{"key":"8218_CR31","doi-asserted-by":"publisher","first-page":"iv238","DOI":"10.1093\/annonc\/mdy308","volume":"29","author":"A Vogel","year":"2018","unstructured":"Vogel A, Cervantes A, Chau I et al (2018) Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 29:iv238\u2013iv255","journal-title":"Ann Oncol"},{"key":"8218_CR32","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1055\/s-2007-1007122","volume":"19","author":"JM Llovet","year":"1999","unstructured":"Llovet JM, Br\u00fa C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19:329\u2013338","journal-title":"Semin Liver Dis"},{"key":"8218_CR33","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1002\/1097-0142(19850815)56:4<918::AID-CNCR2820560437>3.0.CO;2-E","volume":"56","author":"K Okuda","year":"1985","unstructured":"Okuda K, Ohtsuki T, Obata H et al (1985) Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 56:918\u2013928","journal-title":"Cancer"},{"key":"8218_CR34","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1002\/hep.510280322","volume":"28","author":"CLIP Investigators","year":"1998","unstructured":"Investigators CLIP (1998) A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 28:751\u2013755","journal-title":"Hepatology"},{"key":"8218_CR35","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1111\/jgh.13327","volume":"31","author":"YJ Jin","year":"2016","unstructured":"Jin YJ, Lee SH, Cho SG et al (2016) Prediction of postoperative liver failure using gadoxetic acid-enhanced magnetic resonance imaging in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 31:1349\u20131356","journal-title":"J Gastroenterol Hepatol"},{"key":"8218_CR36","doi-asserted-by":"publisher","first-page":"109189","DOI":"10.1016\/j.ejrad.2020.109189","volume":"130","author":"Y Tsujita","year":"2020","unstructured":"Tsujita Y, Sofue K, Komatsu S et al (2020) Prediction of post-hepatectomy liver failure using gadoxetic acid-enhanced magnetic resonance imaging for hepatocellular carcinoma with portal vein invasion. Eur J Radiol 130:109189","journal-title":"Eur J Radiol"},{"key":"8218_CR37","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1007\/s00595-020-02062-y","volume":"50","author":"K Araki","year":"2020","unstructured":"Araki K, Harimoto N, Yamanaka T et al (2020) Efficiency of regional functional liver volume assessment using Gd-EOB-DTPA-enhanced magnetic resonance imaging for hepatocellular carcinoma with portal vein tumor thrombus. Surg Today 50:1496\u20131506","journal-title":"Surg Today"},{"key":"8218_CR38","doi-asserted-by":"publisher","first-page":"580","DOI":"10.2214\/AJR.17.19206","volume":"211","author":"DK Kim","year":"2018","unstructured":"Kim DK, Choi JI, Choi MH et al (2018) Prediction of posthepatectomy liver failure: MRI with hepatocyte-specific contrast agent versus indocyanine green clearance test. AJR Am J Roentgenol 211:580\u2013587","journal-title":"AJR Am J Roentgenol"},{"key":"8218_CR39","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1016\/j.jhep.2018.01.024","volume":"68","author":"AY Kim","year":"2018","unstructured":"Kim AY, Sinn DH, Jeong WK et al (2018) Hepatobiliary MRI as novel selection criteria in liver transplantation for hepatocellular carcinoma. J Hepatol 68:1144\u20131152","journal-title":"J Hepatol"},{"key":"8218_CR40","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1007\/s00330-019-06369-4","volume":"30","author":"CJ Zech","year":"2020","unstructured":"Zech CJ, Ba-Ssalamah A, Berg T et al (2020) Consensus report from the 8th International Forum for Liver Magnetic Resonance Imaging. Eur Radiol 30:370\u2013382","journal-title":"Eur Radiol"},{"key":"8218_CR41","doi-asserted-by":"publisher","first-page":"3532","DOI":"10.1007\/s00261-020-02779-x","volume":"45","author":"S Poetter-Lang","year":"2020","unstructured":"Poetter-Lang S, Bastati N, Messner A et al (2020) Quantification of liver function using gadoxetic acid-enhanced MRI. Abdom Radiol (NY) 45:3532\u20133544","journal-title":"Abdom Radiol (NY)"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-021-08218-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-021-08218-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-021-08218-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,5]],"date-time":"2023-02-05T21:09:44Z","timestamp":1675631384000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-021-08218-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,31]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["8218"],"URL":"https:\/\/doi.org\/10.1007\/s00330-021-08218-9","relation":{},"ISSN":["0938-7994","1432-1084"],"issn-type":[{"value":"0938-7994","type":"print"},{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,31]]},"assertion":[{"value":"14 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The scientific guarantor of this publication is Max Seidensticker.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"Bernhard Gebauer: Personal fees: Bayer, Sirtex.Irene Bargellini: Grants: Sirtex, during the conduct of the study. Personal fees: Bayer, Sirtex, Biocompatibles, Terumo, outside the submitted work.Maciej Pech: Grants: Sirtex, Bayer; Personal fees: Sirtex.Peter Malfertheiner: Grants: Bayer, Sirtex.Jens Ricke: Grants: Sirtex, Bayer; Personal fees: Sirtex, Bayer.Max Seidensticker: Personal fees: Bayer, Sirtex","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"One of the authors (O\u00d6) has significant statistical expertise.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Written informed consent was obtained from all subjects (patients) in this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Institutional Review Board approval was obtained.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The main results of the clinical trial have been previously reported in <i>Ricke J Hepatology 2019.<\/i>","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study subjects or cohorts overlap:"}},{"value":"\u2022 retrospective\u2022 diagnostic or prognostic study\u2022 multicenter study","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}